We would love to hear your thoughts about our site and services, please take our survey here.
In fairness to CJ39 and where you are slightly bending the information out there to your own angle
"Did Evgen receive ‘up to $6m’ in 2023? Yes, Evgen received $500k from Stalicla"
The 500k wasn't part of that $6m and that was made perfectly clear in the RNS.
It's nice to see a slight pick up in the price, the cynic in me thinks the MM have a massive overhang in stock from the AXA sale and are artificially trying to generate a false dawn to attract more buyers, or it could just be part of a re rating of the whole sector.
Pro I would like your thoughts on when you think Evgen will undertake a new placement and how much they are likely to raise.
Going by the last cash call, they raised funds around 9 months prior to when the cash was due to run out, it would be somewhat suicidal not to bother at all in the hope that Stalicla come through.
They could always borrow the money I suppose which would protect shareholders value but at what cost.
We are all pretty much in agreement that if Stalicla doesn't come through with the funds a cash call is inevitable, Pro how much do you think they'll have to raise in such a scenario, £10m was the last call.
One thing is for certain and why my trust in the bods is so low, prior to any announcement there will be a flurry of positive news promising the earth to ramp the price up.
Huw was in overdrive with positive announcements just prior to the last cash call, that together with his track record when it comes to failed companies doesn't feel me with confidence and why I'm so passionate about making sure that other non suspecting punters don't fall into the same trap.
Well let's work on the facts we have today and assume Stalicla doesn't come through with any cash which is a very real possibility. How much would you expect them to have to raise under those circumstances ?
I used £10 million as an example because that is what they previously did.
The Bods have completely messed this up by allowing the SP to drop so much, these types of companies need a steady stream of funds to survive, but it gets to a point which in my opinion we've gone well past that shareholder value is irreplaceabley damaged and nothing can be salvaged even if the product proves to be successful. They'll be to many shares in issue to be worth anything to existing holders. Give it a year or so and these will be trading at fraction of a pence.
I personally think Huw is not far away from a career suicide, have you seen how many companies have gone into administration under his stewardship.
The company has stated that they will run out of cash by quarter 4, given the choice as to whether to dilute the shares by such a large margin or go into administration due to lack of funds most shareholders would seek the dilution options.
Everything seems to be riding on this Stalicla payment, which to me sounds just like the super Juv deal that never happened.
Talk it up as much as you like, you've got plenty of die hards on here more than happy to lap up your ramping. The reality is that they are running out of cash and a massive share dilution is the only thing that will keep the company afloat
If they try and raise £10 million again at today's price they'll have to issue around 666 million shares, add that to the current issue of 275 million they'll have a hefty 941 million shares in issue. If these ever got back to 10p, it would value the company at £94 million. Can you now see why any share dilution is a complete disaster for existing holders and why the bods are reluctant to buy.
AXA probably got wind of a new placement, they are either getting out all together as the dilution at these levels will probably wipe out any potential future share price growth, or alternatively are freeing up cash to participate at a much lower placement price. I personally think they are cutting their losses.
Broom, just to add a little context, staff could subscribe to £3600 worth of shares at 1.12, that would equate to approximately £7200 at today's market price. Admittedly not everyone has sold at the first opportunity but the ones that have would have had an impact as demonstrated by the share price movement compared to both Lloyds and Barclays
Contrary to all the posts this morning, the reason for the sell of is that staff 3 year share options matured with a strike price of £1.124 pence. The selling is down to staff taking their near 100% return. And before some smart ar-s suggests they know something hence the selling, it's purely down to the average employee isn't paid much and historically it's a decent return
Like the majority of AIM shares they need a constant supply of fuel in this case news to keep the share price fire raging. It's definitely smouldering at the moment and some may even think it's gone out, but as anyone who has had a bonfire knows, add a little combustible material and this will be raging again.
It should give us all a great deal of confidence that the bods are so heavily invested. So many AIM companies where the bods talk a good book but have zero skin in the game, Evgen is a prime example
You may or may not be into technical analysis, but it seems we formed an inverted hammer today using candlestick.
What Is the Inverted Hammer Candlestick?
The Inverted Hammer candlestick formation occurs mainly at the bottom of downtrends and can act as a warning of a potential bullish reversal pattern. What happens on the next day after the Inverted Hammer pattern is what gives traders an idea as to whether or not prices will go higher or lower.
Read more at: https://commodity.com/technical-analysis/inverted-hammer/
I've now moved this to my long term investment portfolio. FOMO lesson learnt, I say learnt, I'm sure I'll do the same again. I used up my ISA allowance this year so purchased these as a general investment, will look to sell around the 4th April, and then buy back under my ISA. Any loss on these I can offset against profitable company share options.
Could easily turn around overnight, but with AIM it's always best to discount the worst scenario.
I'm glad you find my post so interesting, you can try to discredit me but my share price prediction over the last 3 years speaks for itself. Can I ask, are you employed by Evgen to put down any dissenting voices. Is that what the new strategy is when they said they were working on plans to add to share holder value. Back in the early days money munch used the same tactic as yourself, drown out any negative posts with loads of long winded individual posts.
Keep polishing mate, you'll need plenty of elbow grease with this company.
Cyber, for this type of diagnosis you don't need 000s to confirm it works, and that's why they got the ok to progress so quickly. I can't comment on the short term price movement especially with all the mis information out there, but they have a proven product being adopted by the industry. It's only a matter of time before it's true potential is reflected in the SP.
I've seen some rather daft posts on her over the last few years, this one tops them all.
"Multiple times I've seen references that Kight will be dissatisfied and wishing he had never bought his shares. To this point I would say that none of us knows Kight personally and so cannot suggest how he may or may not feel about his Evgen investment"
He bought in at around 7p and the price is now 1.6p. You really do not have to know Kight personally to know that this is a regrettable trade, arguing differently just highlights your ramping status.
Your cash projection are also way out of line, the bods themselves have said they will run out of funds by the end of 2024, how can you possibly think they'll still have 3m by September 2024.
You stay away for a few weeks and you suddenly have new rampers coming on board trying to polish a T- - d
Lots of posts debating set up costs for production, number of units likely to be sold and whether we will be part of certain pilots or not
Im thinking it's a lot simpler then that, my view is that they go into partnership with a big pharma who will deal with all the marketing and production ect, in return OBD will probably get a large upfront payment and regular royalties stretching way into the future. This will not only fund future research but also regular dividends.